OncLive News Network On Location: ASCO GU 2022 - Episode 1

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

, ,

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.


We are reporting from the 2022 Genitourinary Cancers Symposium!

Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Jathin Bandari and Dr. Tanya Dorff, both on what pivotal prostate cancer studies they are most excited about.

Welcome to OncLive News Network! I’m Gina Mauro.

In patients with metastatic castration-resistant prostate cancer, treatment with olaparib and abiraterone acetate demonstrated a significant improvement in radiographic progression-free survival vs placebo plus abiraterone. The benefit, which was seen in the phase 3 PROpel trial, was specific to patients with newly detected disease who had not received prior frontline therapy and was observed regardless of homologous recombination repair status.

In the phase 3 MAGNITUDE study, the combination of niraparib and abiraterone plus prednisone improved radiographic progression-free survival vs placebo plus AAP, along with other clinically relevant outcomes, in patients with metastatic castration-resistant prostate cancer and who had homologous recombination repair-associated alterations.

Data from the phase 3 ARASENS trial demonstrated that early therapy with darolutamide plus androgen deprivation therapy plus docetaxel showed a significant increase in overall survival vs ADT and docetaxel alone in patients with metastatic hormone-sensitive prostate cancer. The safety profile was similar between the 2 arms.

Continued treatment with enzalutamide in men with mCRPC significantly improved progression-free survival compared with placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer, who progressed on enzalutamide plus ADT, and received post-progression docetaxel plus prednisione.

Finally, results from the SPOTLIGHT trial showcased that 18F-labeled prostate-specific membrane antigen positron emission tomography 7.3has a clinically meaningful correct detection rate that meets the prespecified threshold in patients with recurrent prostate cancer, across a wide PSA range.

Please be sure to check out more of our coverage from the 2022 ASCO GU meeting at OncLive.com.

That’s all for today. Tomorrow, we’ll virtually sit down with Drs Jonathan Rosenberg and Guru Sonpavde, both of whom will share their perspectives on the breaking research in bladder cancer.

Thank you for watching OncLive News Network: On Location, I’m Gina Mauro.